# Abdera Therapeutics

**Canonical:** https://apis.io/providers/abderatherapeutics/  
**Website:** https://www.abderatx.com/  
**APIs profiled:** 0

Abdera Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, with research operations in Vancouver, British Columbia. It was launched in 2021 out of adMare BioInnovations with AbCellera as a founding partner and has raised roughly $148 million from investors including Versant Ventures, Foresite Capital, Johnson & Johnson Innovation (JJDC), Qiming Venture Partners USA, RTW Investments and venBio. The company engineers precision radiopharmaceuticals for solid tumours on its proprietary Radio Optimized Vector Engineering (ROVEr) platform, which pairs antibody-derived targeting vectors with potent alpha-emitting radioisotopes such as actinium-225. Its lead candidate, ABD-147, targets delta-like ligand 3 (DLL3) and is in a Phase 1 trial (NCT06736418) in small cell lung cancer and large cell neuroendocrine carcinoma under FDA Fast Track designation; a second program, ABD-320, targets 5T4. Abdera's product is a drug candidate, not software. It runs no developer program and publishes no API, developer portal, API reference, SDK, or machine-readable specification of any kind. As of 2026-09-06 the company's own corporate site at www.abderatx.com was additionally unreachable, returning a Flywheel "Unknown Domain" host error on every path behind a TLS certificate that expired on 2026-07-19.

## Kin Score — 2.9 / 100 (minimal)

Scored 2026-09-06 under rubric 0.19.0.

| Facet | Score |
|---|---|
| Discoverability | 46.3 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 7.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |

## Security (1)

- **Abderatherapeutics Domain Security** — DMARC

## Tags

Company, Biotechnology, Pharmaceuticals, Radiopharmaceuticals, Oncology, Drug Development, Clinical Trials, Life Sciences

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/abderatherapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.